BRIEF-GSK announces positive results from two phase III studies of Incruse Ellipta

June 11 Wed Jun 11, 2014 7:48am EDT

June 11 (Reuters) - Glaxosmithkline Plc

* Incruse ellipta positive data studies

* GSK and Theravance announce positive data from two studies evaluating efficacy and safety of incruse  ellipta  when added to Relvar  /Breo  Ellipta  in patients with COPD

* Studies showed that for primary endpoint of trough fev1 at day 85, addition of umec 62.5mcg or umec 125mcg to ff/vi 100/25mcg resulted in a statistically significant improvement in lung function when compared with ff/vi 100/25mcg plus placebo in patients with copd. Source text for Eikon: Further company coverage:

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.